Xencor extends cash runway estimate through 2028

Xencor, Inc. (NASDAQ: XNCR) has updated its cash runway forecast, projecting that its existing cash and cash equivalents will be sufficient to fund operations through 2028, according to a recent SEC filing. This extension reflects the company’s ongoing efforts to optimize operational efficiency and manage expenses amid its clinical development programs.

As of the most recent quarter, Xencor reported $480 million in cash and cash equivalents. The company expects to maintain this runway through 2028 based on its current operating plan, which includes anticipated expenses related to its pipeline of antibody-based therapeutics and collaborations with biopharmaceutical partners.

The updated forecast provides Xencor with additional flexibility as it advances multiple programs, including partnered assets in oncology and autoimmune diseases. The company emphasized that the extended runway is based on current assumptions and could change depending on pace of clinical development, regulatory requirements, and other operational factors. Investors are advised to monitor future financial reports for updates to this projection.